Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation

Chest

Volumn 115, Issue 3, 1999, Pages 836-847

  Anker, Stefan D ^a,b   Coats, Andrew J S ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Body wasting; Chronic heart failure; Cytokines; Immune activation; Neurohormonal activation; Neurohormones; Weight loss

Indexed keywords

ALDOSTERONE; CATECHOLAMINE; HYDROCORTISONE; RENIN; SODIUM; TUMOR NECROSIS FACTOR ALPHA;

BLOOD LEVEL; BODY COMPOSITION; CACHEXIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FUNCTIONAL ASSESSMENT; HEART FAILURE; HUMAN; IMMUNOPATHOLOGY; NEUROENDOCRINE DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; WEIGHT REDUCTION;

EID: 0033035459     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.3.836     Document Type: Review

References (101)

1. 1 Katz AM, Katz PB. Diseases of heart in works of Hippocrates. Br Heart J 1962; 24:257-264
2. 2 Aronson JK. An account of the foxglove and its medical uses. London: Oxford University Press, 1985; 11-100
3. 3 Kushner RF. Body weight and mortality. Nutr Rev 1993; 51:127-136
4. 4 Brozek J, Wells S, Keys A. Medical aspects of semistarvation in Leningrad (siege 1941-1942). Am Rev Sov Med 1946; 4:70-86
5. 5 Cahill GF Jr. Starvation in man. N Engl J Med 1970; 282:668-675
6. 6 Iribarren C, Sharp DS, Burchfiel CM, et al. Association of weight loss and weight fluctuation in Japanese American men. N Engl J Med 1995; 333:686-692
7. 7 Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women N Engl J Med 1995; 333:677-685
8. 8 Byers T. Body weight and mortality. N Engl J Med 1995; 333:723-724
9. 9 Kuczmarski RJ. Need for body composition information in elderly subjects. Am J Clin Nutr 1989; 50:1150-1157
10. 10 Rossman I. Anatomic and body composition changes with aging. In: Finch CE, Hayflick L, eds. Handbook of the biology of aging. New York, NY: Von Nostrand Reinhold, 1977; 189
11. 11 Borkan GA, Hults DE, Gerzof SG, et al. Age changes in body composition revealed by computed tomography. J Gerontol 1983; 38:673-677
12. 12 Wallace JI, Schwartz RS. Involuntary weight loss in elderly outpatients: recognition, etiologies, and treatment. Clin Geriatr Med 1997; 13:717-735
13. 13 Friedlaender JS, Costa PT Jr, Bosse R, et al. Longitudinal physique changes among healthy white veterans at Boston. Hum Biol 1977; 49:541-558
14. 14 Chumlea WC, Carry PJ, Hunt WC, et al. Distributions of serial changes in stature and weight in a healthy elderly population. Hum Biol 1988; 60:917-925
15. 15 Hammond EC, Garfinkel L. Coronary artery disease, stroke, and aortic aneurysm: factors in the etiology. Arch Environ Health 1969; 19:167-182
16. 16 Wallace JI, Schwartz RS, LaCroix AZ, et al. Involuntary weight loss in older outpatients: incidence and clinical significance. J Am Geriatr Soc 1995; 43:329-337
17. 17 Wadden TA. Treatment of obesity by moderate and severe caloric restriction: results of clinical research trials. Ann Intern Med 1993; 119:688-693
18. 18 Roberts SB, Fuss P, Heyman MB, et al. Control of food intake in older men. JAMA 1994; 272:1601-1606 (erratum published: JAMA 1995; 273:702)
19. 19 New weight standards for men and women. Stat Bull Metrop Life Insur Co 1959; 40:1
20. 20 Society of Actuaries and Association of Life Insurance Medical Directors of America. Build study, 1979. Philadelphia, PA: Recording and Statistical Corporation, 1980
21. 21 Anker SD, Coats AJS. The syndrome of cardiac cachexia in chronic heart failure. In: Poole-Wilson PA, Colucci WS, Massie BM, et al, eds: Heart failure. New York, NY: Churchill-Livingstone, 1996; 261-267
22. 22 Carr JG, Stevenson LW, Walden JA, Heber D. Prevalence and hemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989; 63:709-713
23. 23 McMurray J, Abdullah I, Dargie HJ, et al. Increased concentrations of tumor necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 1991; 66:356-358
24. 24 Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241
25. 25 Otaki M. Surgical treatment of patients with cardiac cachexia: an analysis of factors affecting operative mortality. Chest 1994; 105:1347-1351
26. 26 Freeman LM, Roubenoff R. The nutrition implications of cardiac cachexia. Nutr Rev 1994; 52:340-347
27. 27 Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121:951-957
28. 28 Abel RM, Fischer J, Buckley MJ, et al. Malnutrition in cardiac surgical patients. Arch Surg 1976; 111:45-50
29. 29 Blackburn GL, Gibbons GW, Bothe A, et al. Nutritional support in cardiac cachexia. J Thorac Cardiovasc Surg 1977; 73:489-495
30. 30 Ansari A. Syndromes of cardiac cachexia and the cachectic heart: current perspectives. Prog Cardiovasc Dis 1987; 30:45-60
31. 31 Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor of survival in chronic heart failure. Lancet 1997; 349:1050-1053
32. 32 Anker SD, Coats AJS. Cachexia in heart failure is bad for you. Eur Heart J 1998; 19:191-193
33. 33 Lipkin DP, Jones DA, Poole-Wilson PA. Abnormalities of skeletal muscle in patients with chronic heart failure. Int J Cardiol 1988; 18:187-195
34. 34 Drexler H, Riede U, Münzel T, et al. Alterations of skeletal muscle in heart failure. Circulation 1992; 85:1751-1759
35. 35 Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992; 85: 1364-1373
36. 36 Minotti JR, Christoph I, Weiner MW, et al. Impaired skeletal muscle function in patients with congestive heart failure. J Clin Invest 1991; 88:2077-2082
37. 37 Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 1997; 30:1758-1764
38. 38 Anker SD, Swan JW, Volterrani M, et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J 1997; 18:259-269
39. 39 Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev 1991; 49:163-175
40. 40 Kotler DP, Tiermey AR, Wang J, et al. Magnitude of body cell mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989; 50:444-447
41. 41 Thomas RD, Silverton NP, Burkinshaw L, et al. Potassium depletion and tissue loss in chronic heart disease. Lancet 1979; 310:9-11
42. 42 Lee AH, Rebekah LM, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 1994; 96:35-41
43. 43 Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999 (in press)
44. 44 Toth MJ, Gottlieb SS, Goran MI, et al. Daily energy expenditure in free-living heart failure patients. Am J Physiol 1997; 272:469-475
45. 45 Anker SD, Clark AL, Teixeira MM, et al. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1998; 83:612-615
46. 46 Volterrani M, Clark AL, Ludman PF, et al. Predictors of exercise capacity in chronic heart failure. Eur Heart J 1994; 15:801-809
47. 47 Pittman JG, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med 1964; 271:403-409
48. 48 Buchanan N, Keen RD, Kingsley R, et al. Gastrointestinal absorption studies in cardiac cachexia. Intensive Care Med 1977; 3:89-91
49. 49 King D, Smith ML, Chapman TJ, et al. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing 1996; 25:144-149
50. 50 King D, Smith ML, Lye M. Gastro-intestinal protein loss in elderly patients with cardiac cachexia. Age Ageing 1996; 25:221-223
51. 51 Braunwald E. Clinical manifestation of heart failure. In: Heart disease. A textbook of cardiovascular medicine (vol 1). Philadelphia, PA: WB Saunders, 1984; 499
52. 52 MacGowan GA, Mann DL, Kormos RL, et al. Circulating IL-6 in severe heart failure. Am J Cardiol 1997; 79:1128-1131
53. 53 Anker SD, Chua TP, Swan JW, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: the importance for cardiac cachexia. Circulation 1997; 96:526-534
54. 54 Vescovo G, Serafini F, Facchin L, et al. Specific changes in skeletal muscle myosin heavy chains composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis. Heart 1996; 76:337-343
55. 55 Simioni A, Long CS, Yue P, et al. Heart failure in rats causes changes in skeletal muscle phenotype and gene expression unrelated to locomotor activity [abstract]. Circulation 1995; 92(Suppl 1):I-259
56. 56 Poehlman ET, Scheffers J, Gottlieb SS, et al. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med 1994; 121:860-862
57. 57 Poehlman ET, Danforth E. Endurance training increases metabolic rate and norepinephrine appearance rate in older individuals. Am J Physiol 1991; 261:E233-E239
58. 58 Cohn AE, Steele JM. Unexplained fever in heart failure. J Clin Invest 1934; 13:853-868
59. 59 Dutka DP, Elborn JS, Delamere F, et al. Tumor necrosis factor α in severe congestive cardiac failure. Br Heart J 1993; 70:141-143
60. 60 Nathan CF. Secretary products of macrophages. J Clin Invest 1987; 79:319-326
61. 61 Hsi ED, Remick DG. Monocytes are the major producers of IL-1b in an ex vivo model of local cytokine production. J Interferon Cytokine Res 1995; 15:89-94
62. 62 Torre-Amione G, Kapadia S, Lee J, et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92:1487-1493
63. 63 Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93:704-711
64. 64 Mann DL. Stress activated cytokines and the heart. Cytokine Growth Factor Rev 1996; 7:341-354
65. 65 Anker SD, Egerer K, Volk H-D, et al. Elevated soluble CD14 receptors and and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79:1426-1430
66. 66 Tracey KJ, Morgello S, Koplin B, et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production: cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest 1990; 86:2014-2024
67. 67 Kitajima I, Kawahara K, Nakajima T, et al. Nitric oxide-mediated apoptosis in murine mastocytoma. Biochem Biophys Res Commun 1994; 204:244-251
68. 68 Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996; 98:2854-2865
69. 69 Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1994; 10:317-43
70. 70 Yoshizumi M, Perella MA, Burnett JCJ, et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 733:205-209
71. 71 Anker SD, Volterrani M, Egerer KR, et al. Tumor necrosis factor-α as a predictor of peak leg blood flow in patients with chronic heart failure. Q J Med 1998; 91:199-203
72. 72 Francis GS. Neurohormonal mechanisms involved in congestive heart failure. Am J Cardiol 1985; 55(Suppl A):15A-21A
73. 73 Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248-254
74. 74 Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823
75. 75 Swedberg K, Eneroth P, Kjekskus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82:1730-1736
76. 76 Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993; 87(Suppl VI):VI-40-VI-48
77. 77 Goldstein DS. Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. Am J Cardiol 1981; 48:1147-1154
78. 78 Landsberg L, Young JB. Catecholamines and the adrenal medulla. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology. Philadelphia, PA: WB Saunders, 1992; 621-705
79. 79 Chidsey CA, Harrison DC, Braunwald E. The augmentation of plasma norepinephrine response to exercise in patients with congestive heart failure. N Engl J Med 1962; 267:650-654
80. 80 Orth DN, Kovacs WJ, DeBold CR. The adrenal cortex. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology. Philadelphia, PA: WB Saunders, 1992; 489-619
81. 81 Anand IS, Ferrari R, Kalra GS, et al. Edema of cardiac origin: studies on body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989; 80:299-305
82. 82 Nicholls MG, Espiner EA, Donald RA, et al. Aldosterone and its regulation during diuresis in patients with gross congestive heart failure. Clin Sci Mol Med 1974; 47:301-315
83. 83 Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997; 30:997-1001
84. 84 Anker SD, Coats AJS. Metabolic, functional, and haemodynamic staging for CHF? Lancet 1996; 348:1530-1531
85. 85 Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18:858-865
86. 86 Anker SD. Catecholamine levels and treatment in chronic heart failure. Eur Heart J 1998; 19(Suppl F):F56-F61
87. 87 Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995; 76:803-808
88. 88 Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995; 92:1479-1486
89. 89 Broqvist M, Arnqvist H, Dahlström U, et al. Nutritional assessment and muscle energy metabolism in severe congestive heart failure: effects of long-term dietary supplementation. Eur Heart J 1994; 15:1641-1650
90. 90 Heymsfield SB, Casper K. Congestive heart failure: clinical management by use of continuous nasoenteric feeding. Am J Clin Nutr 1989; 50:539-544
91. 91 Coats AJS, Adamopoulos S, Meyer TE, et al. Effects of physical training in chronic heart failure. Lancet 1990; 335:63-66
92. 92 Coats AJS, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Circulation 1992; 85:2119-2131
93. 93 Endres S, Ghorbani R, Kelley V, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of IL-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320:265-271
94. 94 Kremer JM, Jubiz W, Michalek A, et al. Fish-oil fatty acid supplementation in active rheumatoid arthritis: a double-blinded, controlled, crossover study. Ann Intern Med 1987; 106:497-503
95. 95 Van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α. Proc Natl Acad Aci USA 1992; 89:4845-4849
96. 96 Deswal A, Seta Y, Blosch CM, et al. A phase I trial of tumor necrosis factor (p75) fusion protein (TNPR:Fc) in patients with advanced heart failure [abstract]. Circulation 1997; 96(Suppl):I-323
97. 97 Sliwa K, Skudicky D, Candy G, et al. Randomised trial of effects of pentoxiphylline on left-ventricular performance in ideopathic dilated cardiomyopathy. Lancet 1998; 351:1091-1093
98. 98 Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351:1233-1237
99. 99 Cuneo RC, Wilmshurst, P, Lowy, et al. Cardiac failure responding to growth hormone. Lancet 1989; 333:838-839
100. 100 O'Driscoll JG, Green DJ, Ireland M, et al. Treatment of end-stage cardiac failure with growth hormone. Lancet 1997; 349:1068
101. 101 Cowie MR, Mosterd AA, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1997; 18:208-225